TCI Wealth Advisors’s UroGen Pharma URGN Stock Holding History

TCI Wealth Advisors’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-13	Closed	–	–	1686
2019 Q3	$0	Buy	+13	New	+$425	﹤0.01%	1633

Other funds holding URGN

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

WCM

Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return

HCM

Highline Capital Management New York $53.5M AUM 21.72% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCI Wealth Advisors's URGN Position: Q4 2019 in Review

TCI Wealth Advisors sold out of UroGen Pharma (URGN) in Q4 2019, closing a stake of 13 shares.

TCI Wealth Advisors first reported a position in URGN in Q3 2019 and held it in 1 quarter. The position peaked at $0 in Q3 2019. 86 funds tracked by Wall St. Rank hold URGN as of Q4 2019.

TCI Wealth Advisors reported no remaining UroGen Pharma position as of Q4 2019 after selling out during the quarter.
TCI Wealth Advisors sold 13 UroGen Pharma shares in Q4 2019.
TCI Wealth Advisors first reported a position in UroGen Pharma in Q3 2019 and held it in 1 quarter.
TCI Wealth Advisors's UroGen Pharma position peaked at $0 in Q3 2019.
86 funds tracked by Wall St. Rank held UroGen Pharma as of Q4 2019.

Based on TCI Wealth Advisors's 13F filing for Q4 2019, filed 27 Jan 2020.